Categories
Blood Cancer

A comparison of bispecific antibodies emerging in multiple myeloma [Video]

Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, gives a brief overview of bispecific antibodies emerging for the treatment of multiple myeloma, highlighting the main differences between BCMA-targeting and GPRC5D-targeting agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Are we moving away from transplantation for the treatment of myeloma? [Video]

Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares some insights into the future treatment landscape of multiple myeloma, drawing focus on the role of transplantation and whether treatment will move away from this approach. Dr Schjesvold highlights the DETERMINATION trial (NCT01208662) and also mentions upcoming trials investigating this, as well as the role of bispecifics in the future of myeloma therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

MagnetisMM-3: elranatamab in relapsed/refractory multiple myeloma [Video]

Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma. Patients enrolled were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Preliminary results of MagnetisMM-3 in patients with relapsed/refractory myeloma and no prior BCMA-targeted treatment suggest that 76 mg of elranatamb adminstered once weekly with a 2-step-up priming regimen is well tolerated, with no grade 3 cytokine release syndrome or immune effector cell-assciated neurotoxicity syndrome (ICANS) observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving? [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Future perspectives on CAR-T therapy for multiple myeloma [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, highlights some of the ongoing research in CAR-T therapy for multiple myeloma including increasing capacity and speed of production, as well as increasing expression of BCMA, and a new target being currently evaluated – GPRC5D. Prof. Munshi also notes that some patients treated with CAR-T are benefiting from longer-term maintenance, potentially paving the way for a cure in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T updates in myeloma [Video]

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some insights into recent updates in CAR-T therapy for the treatment of multiple myeloma. Prof. Raje first discusses how the approval of ciltacabtagene autoleucel (cilta-cel) has improved options for triple-class refractory and penta-refractory patients, and further explains the promise of idecabtagene vicleucel (ide-cel) and the importance of real-world data. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Peak ALC after CAR-T infusion predicts clinical response in aggressive lymphoma [Video]

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the association between peak absolute lymphocyte count (ALC) after CAR-T infusion and clinical response in aggressive lymphoma. A higher absolute lymphocyte ALC peak was associated with increased complete response rates and a longer duration of response in the first 6 months post-CAR-T cell infusion. Increasing ALC levels also correlated with CAR-T cell expansion and higher rates of progression-free survival (PFS) and overall-survival (OS). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Quadruplet induction therapy as a new standard of care in multiple myeloma [Video]

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, comments on the tolerability and efficacy of quadruplet induction regimens in transplant-eligible and transplant-ineligible patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Current & emerging treatments for patients with triple-class refractory multiple myeloma [Video]

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, outlines current and emerging treatment strategies for patients with triple-class refractory multiple myeloma, which currently include belantamab mafodotin and selinexor. The recent introduction and development of CAR-T therapy and bispecific antibodies in this setting is changing the treatment landscape of patients with triple-class refractory disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

MRD-guided therapy in multiple myeloma [Video]

Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease (MRD)-guided therapy in multiple myeloma, highlighting key clinical trials using MRD to guide discontinuation of maintenance therapy and explaining the importance of better understanding how to both escalate and de-escalate therapy in patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.